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Abstract
Background: The purpose of this study was to investigate the effects of extra corporeal shock
waves (ESW) therapy on the metabolism of healthy and osteoarthritic human chondrocytes, and
particularly on the expression of IL-10, TNF-alpha and beta1 integrin.
Methods: Human adult articular cartilage was obtained from 9 patients (6 male and 3 females),
with primary knee osteoarthritis (OA), undergoing total joint replacement and from 3 young
healthy donors (HD) (2 males, 1 female) with joint traumatic fracture. After isolation, chondrocytes
underwent ESW treatment (electromagnetic generator system, MINILITH SL1, STORZ MEDICAL)
at different parameters of impulses, energy levels and energy flux density. After that, chondrocytes
were cultured in 24-well plate in DMEM supplemented with 10% FCS for 48 hours and then beta1
integrin surface expression and intracellular IL-10 and TNF-alpha levels were evaluated by flow-
cytometry.
Results: At baseline, osteoarthritic chondrocytes expressed significantly lower levels of beta1
integrin and higher levels and IL-10 and TNF-alpha levels. Following ESW application, while beta1
integrin expression remain unchanged, a significant decrease of IL-10 and TNF-alpha intracellular
levels was observed both in osteoarthritic and healthy chondrocytes. IL-10 levels decreased at any
impulses and energy levels, while a significant reduction of TNF-alpha was mainly found at middle
energies.
Conclusion: Our study confirmed that osteoarthritic chondrocytes express low beta1 integrin and
high TNF-alpha and IL-10 levels. Nonetheless, ESW treatment application down-regulate the
intracellular levels of TNF-alpha and IL-10 by chondrocytes, suggesting that ESW might restore
TNF-alpha and IL-10 production by osteoarthritic chondrocytes at normal levels. However, further
in vivo and in vitro studies are necessary to establish if ESW can represent a viable option in the
treatment of OA.
Published: 31 January 2008
BMC Musculoskeletal Disorders 2008, 9:16 doi:10.1186/1471-2474-9-16
Received: 7 September 2007
Accepted: 31 January 2008
This article is available from: http://www.biomedcentral.com/1471-2474/9/16
© 2008 Moretti et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Musculoskeletal Disorders 2008, 9:16 http://www.biomedcentral.com/1471-2474/9/16
Page 2 of 7
(page number not for citation purposes)
Background
Extra-corporeal shock waves (ESW) are expanding their
applications from urinary calculi treatment to orthopae-
dic settings. Recent studies have provided some evidence
that ESW may be useful in treating osteoarthritis (OA) in
animals, such as dogs [1], and horses [2]. In humans, ESW
therapy is widely used for the treatment of several medical
disorders such as plantar fascitis, calcifying tendonitis,
femoral head necrosis and pseudoarthrosis, and more
recently has been proposed as therapy for human OA.
However, whether and how ESW hamper the biologic
processes taking place in articular cartilage that cause OA
is unknown.
In OA, cartilage damage is the outcome of an abnormal
extra-cellular matrix (ECM) remodelling leading to an
overwhelm of tissue breakdown mediated by metallopro-
teinases (MMPs). The pathogenesis of OA is rather intri-
cate and not yet completely understood, however some
events are currently assumed to be critical points in the
induction of cartilage injury [3]. Under physiological set-
tings, chondrocytes sense the changes of surrounding
environment and this signalling between chondrocytes
and ECM is crucial in maintaining cartilage homeostasis.
These chondrocyte/ECM interactions are regulated by a
large family of transmembrane glycoproteins whereby
beta1 integrins are the most widely expressed and interact
with several matrix proteins such as collagen, fibronectin,
vitronectin and laminin [4]. Furthermore, beta1 integrin
cooperate along with growth factor receptors (GFr), such
as TGFbeta, IL-4, and IGF, to activate intracellular ana-
bolic processes [4]. In OA, beta1 integrin expression is sig-
nificantly reduced in damaged cartilage [5] and this
would alter chondrocyte/ECM interactions and disrupt
beta1 integrin/GFr synergy leading to activation of cata-
bolic pathways, increase of MMPs expression and induc-
tion of chondrocyte apoptosis.
The over-expression of MMPs is induced by several
cytokines, such as IL-1, TNF-alpha, IL-17, IL-10, and many
others, which have been detected increased in OA carti-
lage. TNF-alpha is produced by inflamed synovial mem-
brane, chondrocytes and osteoblasts, and act in an
autocrine-paracrine manner. It increases the synthesis of
MMPs and plasminogen activator, essential to convert the
pro-MMPs in MMPs, and regulate the organization of
ECM by enhancing the synthesis of minor collagens, nor-
mally not present in cartilage, such as collagen types I and
III, and decreasing the production of proteoglycans and
collagen types II and IX, which represent the optimal scaf-
folding of cartilage [3]. The biological activities of TNF-
alpha are regulated by two specific cell-surface receptors
TNF-R55 and TNF-R75; the former is mainly involved in
signal transduction in articular tissue cells and its expres-
sion is up-regulated on osteoarthritic chondrocytes and
synoviocytes, that in turn show an increased sensitivity to
TNF-alpha [6,7].
IL-10 activates a broad range of functional responses in
different cell types inducing either inhibitory or stimula-
tory effects, such as down-regulating IL-1 and TNF-alpha
synthesis by monocytes [8] or promoting the growth and
differentiation of B cells [9]. Increased expression of IL-10,
both at protein and mRNA level, has been detected in OA
human cartilage [10], but its role in OA pathogenesis need
to be further investigated.
The purpose of this study has been to evaluate the effects
of ESW on the metabolism of human OA chondrocytes
"in vitro", and particularly on the expression of beta1
integrin, IL-10, and TNF-alpha.
Methods
Chondrocyte isolation
Human articular cartilage was obtained from nine
patients (6 males, 3 females, range age 55–70 years) with
primary knee OA, undergoing total joint replacement at
our orthopaedic department and from three young
healthy donors (HD) (2 males, 1 female, range age 21–37
years) with joint traumatic fracture. We received the
approval for our study from the Poloclinical Ethical Com-
mettee of Bari. All patients gave a written informed con-
sent and the study was approved by the local ethical
committee. Cartilage was taken from the femoral and tib-
ial sides of knee, minced and chondrocytes were isolated
as previously described [10]. Briefly, chondrocytes were
released from the cartilage matrix by hyaluronidase
(0.2%, 30 min., 37°C, Sigma), pronase (0.25%, 90 min.,
37°C, Sigma) and collagenase (0.2%, 3 hours, 37°C,
Sigma) sequential enzymatic digestion. More than 95% of
the chondrocytes were viable (Trypan blue exclusion test)
after their isolation.
ESW treatment
After isolation, chondrocytes were re-suspended in Dul-
becco's modified Eagle medium (DMEM), supplemented
with 10% foetal calf serum (FCS) and antibiotics (penicil-
lin 100 UI/ml and streptomycin 100 microg/ml 5% and
placed in 1,8 ml cryogenic vials (Nunc, Denmark) at 4–5
× 105/cells/ml. The vials were completely filled with
medium and were tested to be permeable for the shock
wave. The ESW electromagnetic generator system (MINI-
LITH SL1, STORZ MEDICAL) was used in this study. This
ESW device is a focused one, and the location was pro-
vided with a ultrasound-guided system. Between the gen-
erator and the cells we used an ultrasound gel that was
compressed to guaranteed to avoid air. The test-vial was
placed in a special cylindrical support on the shockwave
generator, which enabled the focal depth probe to be
directed correctly to the vial containing the cells.BMC Musculoskeletal Disorders 2008, 9:16 http://www.biomedcentral.com/1471-2474/9/16
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Chondrocytes were subdivided into 5 populations: 4 spec-
imens underwent ESW treatment at different parameters
of impulses, energy levels and energy flux density, as
shown in Table 1, while an untreated vial was kept as con-
trol sample, but underwent the same laboratory process-
ing. The controls vials also were kept outside the
incubator for the same time as the treated cells. At the end
of the treatment, cellular vitality was evaluated with the
Trypan blue dye exclusion test, and chondrocytes were
cultured in 24-well plate in DMEM supplemented with
10% FCS for 48 hours prior to flow-cytometry.
Chondrocyte phenotype
After incubation, chondrocytes were re-suspended in PBS
containing 0.1% sodium azide and 0.2% bovine serum
albumin, and blocked by incubating with 2% normal
human serum (Advanced Protein Products, UK). After fix-
ation with paraformaldehyde and permeabilization with
saponin (Fix & Perm Cell Permeabilization Kit, Caltag
Lab., Burlingame, CA), chondrocytes were incubated (20
min. at 4°C) with 5 microl of FITC/anti-human IL-10
mAb or FITC/anti-human TNF-alpha mAb (Serotec,
Oxford, UK). Beta1 integrin (Serotec, Oxford, UK) surface
expression was assessed with the same procedure without
cell membrane permeabilization. Control samples were
incubated with rat IgG1-FITC/IgG2-PE (DAKO, Den-
mark). Stained cells were analyzed on a FACScan (Cell
Quest, Becton Dickinson, Mountain View, CA). The FACS
setting was identical throughout all the study.
Statistical analysis
Results are expressed as mean values ± 1 standard devia-
tion (SD). The Student's t test was used to compare the
treated chondrocytes with the control group and the level
of significance was set at p < 0.05.
Results
Cell viability
The Trypan blue dye exclusion test showed that ESW
application affected chondrocytes viability. Cell viability
was lower in ESW treated chondrocytes than control, both
in OA chondrocytes and in normal chondrocytes,
although these differences did not reach the significance
level. Relevant changes in chondrocyte viability were not
seen according to ESW energy levels and pulses applied
(Table 2).
As shown on Figure 1, the percentage of chondrocytes
bearing beta1 integrin was lower in OA (30.8 ± 6) than in
normal cartilage (53.2 ± 21) at baseline (p < 0.01), but
ESW treatment did not significantly change beta1 integrin
expression on both OA (A1 32.2 ± 6, A2 32.4 ± 6, B1 31.7 ±
5, B2 33.6 ± 8) and normal chondrocytes (A1 51.5 ± 24, A2
50.4 ± 19, B1 49.7 ± 17, B2 50.6 ± 18).
Intracellular levels of TNF-alpha (Figure 2), were signifi-
cantly higher in OA (28.3 ± 8) than in normal cartilage
(18.2 ± 9) at baseline (p < 0.05). ESW application signifi-
cantly decreased the proportion of chondrocytes express-
ing intracellular TNF-alpha both in OA (A1 25.1 ± 9, A2
23.7 ± 8, B1 21.3 ± 12, B2 22.6 ± 8) and normal cartilage
(A1 15.1 ± 9, A2 11.7 ± 8, B1 10.3 ± 10, B2 12.6 ± 7).
As far as IL-10 concerns, we detected similar results (Fig-
ure 3). The percentage of chondrocytes expressing intrac-
ellular IL-10 were significantly higher in OA (41.9 ± 23)
than in normal cartilage (23.2 ± 10) at baseline (p < 0.01).
Following ESW treatment IL-10 levels significantly
decreased both in OA (A1 33.9 ± 23, A2 32 ± 22, B1 32.5 ±
25, B2 32.9 ± 22) and normal cartilage (A1 15.2 ± 8, A2
10.5 ± 12, B1 14.5 ± 6), except for the strongest ESW appli-
cation (B2 21 ± 9).
Discussion
In this study we provided evidence that ESW modulate
intra-cellular levels of TNF-alpha and IL-10 by human
articular chondrocytes both from osteoarthritic patients
and healthy controls, without affecting beta1 integrin
expression.
Our data confirmed that OA chondrocyte phenotype is
defined by reduced beta1  integrin expression and
increased TNF-alpha and IL-10 levels, as earlier reported
[10-12]. The decrease in beta1 integrin cell surface expres-
sion seems to be an early event in OA pathogenesis and
critical in breaking down the complex ECM/chondrocyte
interactions that maintain cartilage homeostasis [3]. TNF-
alpha plays a crucial role in inducing tissue injury and by
interacting with p55 TNF-alpha receptor contributes to
focal loss of cartilage in OA [11,13]. TNF-alpha activates
MMP and aggrecanase production by chondrocytes
[14,15] and cooperates with other cytokines to degrade 
Table 2: Chondrocyte viability following ESW treatment.
Viability Energy flux density (mJ/mm2) Energy level Impulses
72% ± 10 0,055 2,5 500
69% ± 13 0,055 2,5 1000
77% ± 15 0,17 5 500
74 % ± 18 0,17 5 1000
85 % ± 6 Untreated - -
Table 1: The panel of ESW treatment of chondrocytes.
Chondrocytes Energy flux density 
(mJ/mm2)
Energy level Impulses
A1 0,055 2,5 500
A2 0,055 2,5 1000
B1 0,17 5 500
B2 0,17 5 1000BMC Musculoskeletal Disorders 2008, 9:16 http://www.biomedcentral.com/1471-2474/9/16
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ESW modulation of expression of beta1 integrin on chondrocytes Figure 1
ESW modulation of expression of beta1 integrin on chondrocytes. Surface expression of beta1 integrin on osteoar-
thritic (OA) and healthy (HD) chondrocytes treated with ESW at different impulses and energies (see table 1 for the panel of 
ESW treatment) and untreated (control). Bars represents mean ± 1 standard deviation.
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ESW modulation of intracellular levels of TNF-α in chondrocytes Figure 2
ESW modulation of intracellular levels of TNF-α in chondrocytes. Intracellular levels of TNF-α in osteoarthritic (OA) 
and healthy (HD) chondrocytes treated with ESW at different impulses and energies (see table 1 for the panel of ESW treat-
ment) and untreated (control). Bars represents mean ± 1 standard deviation.
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cartilage matrix [16]. The role of IL-10 on cell metabolism
is controversial as having pleiotropyc functions. On one
side, IL-10 has proanabolic effects, such as promotion of
proteoglycan synthesis by human chondrocytes "in vitro"
[17], prevention of cartilage destruction by reducing IL-1
and TNF-alpha mRNA expression in articular chondro-
cytes [17]; on the other side, IL-10 may also exert procat-
abolic effects as in human fibroblasts it down-regulates
type I collagen mRNA expression and enhances colla-
genase and stromelysin gene expression [18]. This diver-
sity of responses indicates that downstream events
following IL-10 binding may vary depending on the cell
target phenotype and on the environment of that cell,
thus making the role of IL-10 in OA pathogenesis more
intriguing and difficult to understand.
It has been previously shown that ESW induce a dose-
dependent increase in cytotoxicity of cultured human
chondrocytes assessed by the lactate dehydrogenase
(LDH) assay [19], but the possible effects of ESW on the
metabolic pathways that are activated in the pathogenetic
mechanisms of OA were not evaluated. In our study, ESW
application on isolated chondrocytes down-regulated the
intracellular levels of TNF-alpha and IL-10, but no
changes in β1 integrin expression were detected. Further-
more, healthy and OA chondrocytes behaved in a similar
fashion. IL-10 expression significantly decreased in
chondrocytes treated with all levels of energy and
impulses, while TNF-alpha seemed to be selectively
reduced at middle levels. These findings might be due to
the generic cell damage induced by ESW owing to cell via-
bility reduction following the treatment. However, we
believe that those effects are specifically ESW related
because cell viability did not correlated to the level of
energy exposure, beta1 integrin expression did not change
after ESW treatment, chondrocytes were cultured 48 hrs
after ESW application and before phenotyping their via-
bility rose over 90%.
The relevance of these findings can be only object of spec-
ulations at the moment. The reduction of TNF-alpha can
be considered as a protective effect and may prevent
MMPs activation and cartilage degradation. Understand-
ing of IL-10 changes may be controversial as IL-10 can
have both proanabolic and procatabolic effects of tissue
metabolism. Additionally, it remains to be clarified
whether IL-10 decrease is a specific outcome of ESW treat-
ment or mediated by TNF-alpha reduction since it has
been shown that TNF-alpha up-regulates IL-10 expression
in rheumatoid arthritis synovitis [20]. At any case, ESW
treatment seems to be capable to restore TNF-alpha and
IL-10 production by osteoarthritic chondrocytes at nor-
mal levels thus potentially interfering with the pathologic
mechanisms causing cartilage damage in OA and repre-
ESW modulation of intracellular levels of IL-10 in chondrocytes Figure 3
ESW modulation of intracellular levels of IL-10 in chondrocytes. Intracellular levels of IL-10 in osteoarthritic (OA) 
and healthy (HD) chondrocytes treated with ESW at different impulses and energies (see table 1 for the panel of ESW treat-
ment) and untreated (control). Bars represents mean ± 1 standard deviation.
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senting the theoretical rationale for using ESW as therapy
of OA.
It has been recently reported that ESW may be useful to
treat OA in dogs [1], and veterinarians have begun to use
ESW also to treat OA in horses [2]. Our findings seem to
provide the biological clue that ESW can be effective in
treating OA. Nonetheless, further studies are warranted to
implement these preliminary data by evaluating the
effects of ESW on other cellular pathways that are critically
involved in OA pathogenesis such as the regulation of
MMPs, and on other articular tissues affected by OA such
as synovial membrane and subchondral bone.
Conclusion
In our work we have found that ESW application down-
regulate the intracellular levels of TNF-alpha and IL-10 by
chondrocytes. Considering that in osteoarthritic chondro-
cytes the expression of beta1 integrin is low and TNF-alpha
and IL-10 levels are high, we speculate that ESW could
restore TNF-alpha and IL-10 production by osteoarthritic
chondrocytes at normal levels thus potentially interfering
with the pathologic mechanisms causing cartilage damage
in OA. However, further in vivo and in vitro studies are
necessary to establish if ESW can represent a viable option
in the treatment of patients suffering of OA.
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